Twist Bioscience Launches Synthetic RNA Positive Controls For SARS-CoV-2 Encapsulated Minicapsules


Twist Bioscience Corporation TWST has launched specific synthetic RNA positive controls for SARS-CoV-2 encapsulated in stainless steel mini capsules that Imagene SA provided. 

  • The airtight mini capsules provide a stable environment for the RNA controls, allowing cost-effective shipping and storage at room temperature of fragile RNA for an extended period. 
  • In particular, the product enhancement will enable Twist to serve customers in regions that do not have an effective cold chain system or easy access to ultra-cold storage and also allow the use of the controls in point of care settings.
  • This is an expansion of Twist's first agreement with Imagene in July 2019 to use Imagene's DNAshell technology for long-term storage of digital data encoded in DNA. Using Imagene's encapsulation technology, Twist now can ship and store both DNA and RNA products for long periods. 
  • The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome, and are sequence-verified. 
  • Price Action: TWST shares are down 4.81% at $48.14 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!